GSA Capital Partners’s Sutro Biopharma STRO Stock Holding History

GSA Capital Partners’s Portfolio STRO Stock Details STRO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$643K	Sell	25,822 -63,245	-71%	-$1.14M	0.04%	763
2025 Q4	$1.03M	Buy	89,067 +71,583	+409%	+$679K	0.09%	348
2025 Q3	$152K	Buy	+17,484	New	+$149K	0.01%	1480
2024 Q3	–	Sell	-23,540	Closed	-$690K	–	1994
2024 Q2	$690K	Buy	+23,540	New	+$931K	0.05%	767
2023 Q4	–	Sell	-6,775	Closed	-$235K	–	1908
2023 Q3	$235K	Buy	+6,775	New	+$295K	0.02%	1212
2023 Q2	–	Sell	-2,059	Closed	-$95K	–	1931
2023 Q1	$95K	Sell	2,059 -2,344	-53%	-$149K	0.01%	1368
2022 Q4	$356K	Sell	4,403 -12,151	-73%	-$844K	0.04%	816
2022 Q3	$919K	Sell	16,554 -5,258	-24%	-$311K	0.12%	198
2022 Q2	$1.14M	Buy	21,812 +18,268	+515%	+$1.02M	0.17%	98
2022 Q1	$291K	Sell	3,544 -3,597	-50%	-$342K	0.04%	913
2021 Q4	$1.06M	Buy	+7,141	New	+$1.28M	0.13%	184

Other funds holding STRO

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return

Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

KCM

Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

GSA Capital Partners's STRO Position: Q1 2026 in Review

GSA Capital Partners reduced its Sutro Biopharma (STRO) stake by 71% in Q1 2026, selling an estimated $1.14M and leaving 25,822 shares worth $643K. The position accounts for 0.04% of the portfolio, ranked #763.

GSA Capital Partners first reported a position in STRO in Q4 2021 and has held it in 11 quarters since. The position peaked at $1.14M in Q2 2022. 78 funds tracked by Wall St. Rank hold STRO as of Q1 2026.

GSA Capital Partners held 25,822 shares of Sutro Biopharma worth $643K as of Q1 2026.
GSA Capital Partners sold 63,245 Sutro Biopharma shares in Q1 2026, an estimated $1.14M.
Sutro Biopharma made up 0.04% of GSA Capital Partners's portfolio in Q1 2026, its #763 holding.
GSA Capital Partners first reported a position in Sutro Biopharma in Q4 2021 and has held it in 11 quarters since.
GSA Capital Partners's Sutro Biopharma position peaked at $1.14M in Q2 2022.
78 funds tracked by Wall St. Rank held Sutro Biopharma as of Q1 2026.

Based on GSA Capital Partners's 13F filing for Q1 2026, filed 8 May 2026.